JIN 2017Alternative Names: JIN2017
Latest Information Update: 18 May 2012
At a glance
- Originator Jina Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Clinical Phase Unknown Cancer
Most Recent Events
- 18 May 2012 Clinical trials in Cancer (IV)